# A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Study · id `cardio:ct-nct05687890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05687890](<https://clinicaltrials.gov/study/NCT05687890>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05687890

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 255 participants.

## Technical summary

Registry record NCT05687890. Randomized; double masking; primary purpose treatment. Start 2023-05-23 (actual); primary completion 2024-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT05687890, source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)
- Started: 2023-05-23 (actual) (ClinicalTrials.gov record NCT05687890, source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)
- Primary completion: 2024-11-30 (actual) (ClinicalTrials.gov record NCT05687890, source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)
- Completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT05687890, source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05687890, source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05687890-2025-01-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
- Condition: Diabetic Kidney Disease
- Condition: IgA Nephropathy
- Intervention (Drug): Placebo of SC0062
- Intervention (Drug): SC0062 low dose
- Intervention (Drug): SC0062 medium dose
- Intervention (Drug): SC0062 high dose
- Lead sponsor: Biocity Biopharmaceutics Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: a6f16ed3059355b1c84f80a14ac6a8c28353190faaa85cc3e3936fbfa4669760
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
